Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382660 | 1.00 | METAP1 (0.42) | METAP1NAMPTTDP1CYP17A1ATR | |
| SCHEMBL2695265 | 0.90 | METAP1 (0.42) | METAP1NAMPTCYP17A1ATRMME | |
| SCHEMBL27703346 | 0.88 | METAP1 (0.44) | METAP1NAMPTCYP17A1ATRRAB9A | |
| SCHEMBL2693327 | 0.87 | METAP1 (0.43) | METAP1NAMPTCYP17A1ATRRAB9A | |
| SCHEMBL2696598 | 0.86 | GRM5 (0.46) | METAP1NAMPTCYP17A1ATRRAB9A | |
| SCHEMBL69347 | 0.86 | METAP1 (0.45) | METAP1NAMPTCYP17A1ATRRAB9A | |
| SCHEMBL29919808 | 0.86 | METAP1 (0.45) | METAP1NAMPTCYP17A1ATRRAB9A | |
| SCHEMBL8609349 | 0.84 | METAP1 (0.42) | METAP1NAMPTCYP17A1ATRRAB9A | |
| SCHEMBL29039959 | 0.83 | METAP1 (0.44) | METAP1NAMPTTDP1CYP17A1ATR | |
| SCHEMBL7410153 | 0.83 | METAP1 (0.41) | METAP1NAMPTCYP17A1ATRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | METAP1 446/4885NAMPT 557/4885TDP1 4771/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | METAP1 446/4885NAMPT 557/4885TDP1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.